Early diagnosis beneficial in Alzheimer's disease

Practitioner

Volumn 257, Issue 1757, 2013, Pages 15-18

  Allan, Charlotte L ^a   Behrman, Sophie ^b   Ebmeier, Klaus P ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CT2 in Psychiatry   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALZHEIMER DISEASE; ANAMNESIS; CONFERENCE PAPER; EARLY DIAGNOSIS; HUMAN; NEUROIMAGING; PATIENT CARE; PATIENT REFERRAL;

AGED; ALZHEIMER DISEASE; EARLY DIAGNOSIS; HUMANS; MEDICAL HISTORY TAKING; NEUROIMAGING; PATIENT CARE TEAM; REFERRAL AND CONSULTATION;

EID: 84874369625     PISSN: 00326518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Rowan SE. National population projections, series PP2 No. 27. Office for National Statistics. London. 2008
2. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7(3): 263-9
3. Snowden JS, Thompson JC, Stopford CL et al. The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. Brain 2011; 134(Pt 9):2478-92
4. Fearing MA, Bigler ED, Norton M et al. Autopsy-confirmed Alzheimer's disease versus clinically diagnosed Alzheimer's disease in the Cache County Study on Memory and Aging: a comparison of quantitative MRI and neuropsychological findings. J Clin Exp Neuropsychol 2007; 29(5): 553-60 (Pubitemid 46918928)
5. Banerjee S, Owens J. Living well with dementia: a national dementia strategy. Department of Health. London. 2009
6. Roalf DR, Moberg PJ, Xie SX et al. Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging. Alzheimers Dement 2012. Dec 20. pii: S1552-5260(12) 02463-6. doi: 10.1016/j.jalz.2012.10.001. [Epub ahead of print]
7. National Institute for Health and Clinical Excellence. CG42. Supporting people with dementia and their carers in health and social care settings. NICE. London. 2006
8. Whitehead A, Perdomo C, Pratt RD et al. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry 2004; 19(7): 624-33 (Pubitemid 38996839)
9. Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2001; 16(9): 852-7 (Pubitemid 32926767)
10. Winblad B, Cummings J, Andreasen N et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22(5): 456-67 (Pubitemid 46831690)
11. Doody RS, Tariot PN et al. Meta-analysis of six-month memantine trials in Alzheimer's disease. Alzheimers Dement 2007; 3(1): 7-17 (Pubitemid 46076022)
12. National Institute for Health and Clinical Excellence. TA217. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. Review of NICE technology appraisal guidance 111. NICE. London. 2011
13. Dementia. The NICE-SCIE guideline on supporting people with dementia and their carers in health and social care. National Collaborating Centre for Mental Health: The British Psychological Society and Gaskell. London. 2011
14. Aguirre E, Woods RT, Spector A, Orrell M. Cognitive stimulation for dementia: A systematic review of the evidence of effectiveness from randomised controlled trials. Ageing Res Rev 2012; 12(1): 253-62
15. Husebo BS, Ballard C, Sandvik R et al. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ 2011; 343:d4065
16. Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Using antipsychotic agents in older patients. J Clin Psychiatry 2004; 65 Suppl 2: 5-99; discussion 100-02
17. Schneider LS, Tariot PN, Dagerman KS et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355(15): 1525-38 (Pubitemid 44547805)
18. Mittal V, Kurup L, Williamson D et al. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. Am J Alzheimers Dis Other Demen 2011; 26(1): 10-28
19. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008; 69(3): 341-8 (Pubitemid 351549385)
20. Fox C, Crugel M, Maidment I et al. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PloS one 2012; 7(5):e35185
21. Gilman S, Koller M, Black RS et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64(9): 1553-62 (Pubitemid 40617691)
22. Lobello K, Ryan JM, Liu E et al. Targeting beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease. Int J Alzheimers Dis 2012; 2012: 628070
23. Wischik CM, Bentham P, Wischik DJ, Seng KM. O3-04-07: Tau aggregation inhibitor (TAI) therapy with rember" arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimers Dement 2008; 4(4):T167
24. Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol Therap 2012; 134(1): 8-25
25. Ebmeier KP. Normal cognitive decline or dementia? Practitioner 2010; 254(1725): 23-7
26. Scheltens P, Leys D, Barkhof F et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992; 55(10): 967-72